High-Specificity Antibodies for Colorectal Cancer Research
Colorectal cancer (CRC), arising from the colon or rectum, is one of the most commonly diagnosed and deadly malignancies worldwide. Its development is tightly linked to genetic mutations, dysregulated signaling pathways, and cellular heterogeneity.
According to recent global estimates, colorectal cancer remains a major public health challenge. More than 1.9 million new cases are diagnosed each year worldwide, and over 900,000 deaths are attributed to the disease annually. According to IARC (International Agency for Research on Cancer), there are about 1.9 million new colorectal cancer cases and over 900,000 deaths globally per year.
Worryingly, incidence among younger adults is rising individuals under 50 now account for a growing fraction of CRC diagnoses, a trend that underscores the need for improved molecular insights and early detection.
At Atlas Antibodies, we provide a powerful toolkit of primary antibodies backed by Human Protein Atlas database, that help researchers map these molecular changes, define biomarkers, and uncover therapeutic targets in CRC.
Key CRC Markers from Atlas Antibodies
Here are 10 high-value protein markers in colorectal cancer research, with links to corresponding Atlas Antibodies products:
| Marker | Function in CRC | Product ID |
|---|---|---|
| CEACAM5 (CEA) | Classic tumor antigen; overexpressed in colorectal cancers — used clinically for diagnosis/monitoring. | HPA019758 |
| CDK4 | Cell-cycle regulator implicated in CRC proliferation (G1 control). | AMAb91499 / HPA006024 |
| p53 (TP53) | Tumor suppressor frequently mutated in CRC; impacts prognosis and therapy response. | AMAb90956 / HPA051244 |
| CDK2 | Kinase controlling G1 → S transition; often deregulated in CRC cell-cycle control. | AMAb91497 / HPA066915 |
| β-catenin (CTNNB1) | Central effector of Wnt signaling; dysregulation drives CRC tumorigenesis. | AMAb91210 / HPA029159 |
| CD44 | Cancer stem cell marker involved in adhesion, invasion, and metastasis. | HPA005785 |
| MYC | Oncogenic transcription factor frequently upregulated in CRC; drives proliferation and metabolism. | HPA034789 / HPA066556 |
| SATB2 | Diagnostic marker of colorectal origin; helps distinguish CRC from other adenocarcinomas. | HPA001042 / AMAb90635 |
| RBM3 | Stress-response RNA-binding protein; reported associations with favorable prognosis in CRC. | HPA003624 / AMAb90655 |
| Vimentin (VIM) | EMT marker; linked to invasion, mesenchymal transition and metastasis. | HPA001762 / AMAb90516 |
Our CRC-focused white paper showcases a curated panel of validated antibodies, backed by Human Protein Atlas data, tailored for investigating proliferation, stemness, DNA repair, adhesion, immune regulation, and more. These tools support translational research, biomarker discovery, and pre-clinical modeling.
How our Antibodies Advance CRC Research
-
Biomarker Discovery: Use these antibodies to validate expression of prognostic or diagnostic proteins in tumor samples or cell lines.
- Functional Studies: Apply IHC, ICC/IF, or western blot to study pathways like cell cycle (CDK4), DNA repair (p53), Wnt signaling (β-catenin), and stemness (CD44, MYC).
- Translational Models: Integration in patient-derived organoids or xenografts to assess target engagement or drug response.
- EMT & Metastasis Profiling: Track EMT transition using vimentin or SATB2 to uncover mechanisms of invasion and dissemination.
Why Choose Atlas Antibodies?
Atlas Antibodies builds on the scientific foundation of the Human Protein Atlas, providing researchers with antibodies supported by extensive tissue- and cell-level data. Each reagent is developed and validated using standardized protocols, including immunohistochemistry, Western blot, ChIP and immunofluorescence, ensuring high specificity and reproducibility across applications.
Researchers can select from PrecisA Monoclonals for precise epitope targeting or Triple A Polyclonals for broader epitope recognition, depending on experimental needs. The portfolio spans key pathways relevant to colorectal cancer biology, enabling comprehensive and well-structured study designs.
Beyond product quality, Atlas Antibodies offers scientific guidance, technical resources, and global distribution to more than 120 countries, ensuring reliable access and consistent support throughout the research process.